Short Interest in Aditxt, Inc. (NASDAQ:ADTX) Increases By 988.7%

Aditxt, Inc. (NASDAQ:ADTX) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 212,300 shares, an increase of 988.7% from the March 31st total of 19,500 shares. Based on an average trading volume of 361,100 shares, the short-interest ratio is presently 0.6 days. Currently, 10.8% of the shares of the company are sold short.

Hedge Funds Weigh In On Aditxt

An institutional investor recently bought a new position in Aditxt stock. Armistice Capital LLC acquired a new stake in Aditxt, Inc. (NASDAQ:ADTX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 28,000 shares of the company’s stock, valued at approximately $350,000. Armistice Capital LLC owned 11.67% of Aditxt as of its most recent SEC filing. Hedge funds and other institutional investors own 15.54% of the company’s stock.

Aditxt Trading Up 6.8 %

Shares of Aditxt stock opened at $2.53 on Friday. Aditxt has a 52-week low of $2.14 and a 52-week high of $68.08. The company’s 50-day simple moving average is $3.23 and its 200-day simple moving average is $4.58.

Aditxt Company Profile

Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.